Condition (MeSH)
Obesity, Metabolically Benign
ClinicalTrials.gov lists 27 trials for Obesity, Metabolically Benign or a narrower condition beneath it. Bridor has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
27 of the 27 trials are tagged with Obesity, Metabolically Benign itself; the rest are tagged with a narrower condition beneath it.
When did Obesity, Metabolically Benign trials start? (14)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 4 |
| 2024 | 2 |
| 2023 | 2 |
| 2022 | 3 |
| 2021 | 3 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 2 |
Showing 10 of 14 earlier years.
No forecast is made for this condition: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 16 months across 15 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Obesity, Metabolically Benign trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Not applicable | 15 |
| Observational | 10 |
How many Obesity, Metabolically Benign trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 5 |
| Enrolling by invitation | 1 |
| Completed | 15 |
| Unknown status | 5 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Obesity, Metabolically Benign trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Bridor | 1 |
Which drugs are being tested for Obesity, Metabolically Benign? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Inulin | 2 |
| Maltodextrin | 1 |
| Acyl ghrelin | 1 |
Interventions as named in the registry (3)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Biological samples collection | 1 |
| DR10624 for injection | 1 |
| MET-3 | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Obesity, Metabolically Benign? (35)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Cardiorespiratory fitness and submaximal exercise dynamics in normal-weight obesity and metabolically healthy obesity. | European journal of applied physiology | 2024 | Yes |
| Cardiometabolic characteristics of people with metabolically healthy and unhealthy obesity. | Cell metabolism | 2024 | Yes |
| Dorsal striatal response to taste is modified by obesity and insulin resistance. | Obesity (Silver Spring, Md.) | 2023 | Yes |
| Myocardial Tissue-Level Characteristics of Adults With Metabolically Healthy Obesity. | JACC. Cardiovascular imaging | 2023 | Yes |
| Metabolic phenotypes and risk of end-stage kidney disease in patients with type 2 diabetes. | Frontiers in endocrinology | 2023 | Yes |
Showing 5 of 35 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.